Atrial Fibrillation (AFib) Support Group
Atrial fibrillation (AF or afib) is an abnormal heart rhythm (cardiac arrhythmia) which involves the two small, upper heart chambers (the atria). Heart beats in a normal heart begin after electricity generated in the atria by the sinoatrial node spread through the heart and cause contraction of the heart muscle and pumping of blood.
Did anyone see the news article about using stem cells from your own heart to reverse heart failure. They are having significant success with it. I don't know how long it will be till it's covered by insurance, but it sounds like a major breakthrough...and it's about time. I really do think a certain amount of heart failure is behind A-fib. I think the larger atrium causes the A-Fib, not the other way around.
This is wonderful news for the future, but I also hear it's extremely painful...Again, what's a little pain with what some of us have gone through physically and mentally. I think we grasp at every straw...I know I have, and they all broke:)
This is wonderful news for the future, but I also hear it's extremely painful...Again, what's a little pain with what some of us have gone through physically and mentally. I think we grasp at every straw...I know I have, and they all broke:)
.
In research by Mesoblast Ltd. (MSB), 45 patients who had moderate to severe congestive heart failure were given a shot of the Revascor treatment and standard medicines, while 15 didnt receive the experimental drug. The therapy was safe and well- tolerated at all doses, according to results of the Phase II study presented yesterday at an American Heart Association meeting in Orlando, Florida.
Mesoblast said it expects to enter Phase III trials in the first half of next year. Revascor may begin making a profit for the Melbourne-based company by 2015, when the treatment is expected to go on sale, David Stanton and Zara Lyons, analysts at Nomura Holdings Inc., wrote in a Nov. 4 note.
The data was outstanding, Stuart Roberts, an analyst at Bell Potter Securities Ltd. in Sydney, said by telephone today. This is probably the biggest thing in heart failure in 10 years.
Heart Pumping Ability
Those given the lowest dose showed a significant improvement over three months in ejection fraction, with a sustained but less pronounced effect over 12 months.